Enlivex Therapeutics Ltd.
ENLV
$1.09
$0.0454.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 44.88% | 48.35% | 30.30% | 17.22% | 13.52% |
| Total Depreciation and Amortization | -45.09% | -34.73% | -17.17% | -8.63% | 2.01% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -68.44% | -58.96% | 0.10% | 120.59% | -2.51% |
| Change in Net Operating Assets | 59.03% | 33.00% | 47.14% | 411.76% | 12.84% |
| Cash from Operations | 41.02% | 44.70% | 38.43% | 29.71% | 15.94% |
| Capital Expenditure | 21.37% | 56.36% | 97.33% | 97.61% | 98.40% |
| Sale of Property, Plant, and Equipment | 573.67% | 1,624.06% | 2,397.56% | 236.59% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -52.90% | 126.56% | 125.99% | 10.85% | 148.37% |
| Cash from Investing | -31.90% | 134.89% | 129.83% | 73.93% | 136.76% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 875.90% | 1,039.65% | 1,037.45% | 880.00% | 21.58% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3,641.18% | -322.22% | -- | -- | 88.82% |
| Cash from Financing | 982.51% | 1,692.78% | 1,342.50% | 1,105.61% | 35.41% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 101.24% | 105.10% | 101.49% | 101.82% | 79.45% |